Objective： The aim of this study was to investigate the expression of CD147 and matrix metalioprpteinsae 9 （MMP-9） in children with non-Hodgkin＇s lymphoma （NHL） and the relations between expressions of CD147 ＆ ...Objective： The aim of this study was to investigate the expression of CD147 and matrix metalioprpteinsae 9 （MMP-9） in children with non-Hodgkin＇s lymphoma （NHL） and the relations between expressions of CD147 ＆ MMP-9 and the clinical indexes. Methods： Specimens excised from NHL patients were prepared. Expression of CD147 and MMP-9 were tested by SABC immunohistochemistry and its correlation to clinical results were analyzed in this report. Results： The positive rate of CD147 expression was 73% （45/62）, and that of MMP-9 expression was 81% （50/62）. There was a positive correlation between CD147 and MMP-9 expressions. CD147 expression intensity was linked to clinical myelo-infiltration, tumor size, LDH value, and clinical staging （P 〈 0.05）, rather than children age, gender, or immune typing （P 〉 0.05）; MMP-9 expression intensity was linked to myelo-infiltration, and clinical staging （P 〈 0.05）, rather than age, gender, immune typing, tumor size, or LDH value （P 〉 0.05）. Five-year survival rates were 78% （22/28） and 45% （15/34） in CD147 （-）-（＋） and （＋＋）-（＋＋＋） cases respectively, and those were 84% （21/25） and 43% （16/37） in MMP-9 （-）-（＋） and （＋＋）-（＋＋＋） cases respectively, the difference was significant. Conclusion： The elevated expression of CD147 and/or MMP-9 correlates with a poor clinical outcome in patients with NHL.展开更多
文摘Objective： The aim of this study was to investigate the expression of CD147 and matrix metalioprpteinsae 9 （MMP-9） in children with non-Hodgkin＇s lymphoma （NHL） and the relations between expressions of CD147 ＆ MMP-9 and the clinical indexes. Methods： Specimens excised from NHL patients were prepared. Expression of CD147 and MMP-9 were tested by SABC immunohistochemistry and its correlation to clinical results were analyzed in this report. Results： The positive rate of CD147 expression was 73% （45/62）, and that of MMP-9 expression was 81% （50/62）. There was a positive correlation between CD147 and MMP-9 expressions. CD147 expression intensity was linked to clinical myelo-infiltration, tumor size, LDH value, and clinical staging （P 〈 0.05）, rather than children age, gender, or immune typing （P 〉 0.05）; MMP-9 expression intensity was linked to myelo-infiltration, and clinical staging （P 〈 0.05）, rather than age, gender, immune typing, tumor size, or LDH value （P 〉 0.05）. Five-year survival rates were 78% （22/28） and 45% （15/34） in CD147 （-）-（＋） and （＋＋）-（＋＋＋） cases respectively, and those were 84% （21/25） and 43% （16/37） in MMP-9 （-）-（＋） and （＋＋）-（＋＋＋） cases respectively, the difference was significant. Conclusion： The elevated expression of CD147 and/or MMP-9 correlates with a poor clinical outcome in patients with NHL.
